홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
ACIU
#6082
AC Immune SA
2.9
3
-0.34%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
-0.34%
월간 변동
-17.93%
6달 변화
+42.23%
년간 변동율
+14.45%
이전 종가
2.9
4
Open
2.9
3
Bid
Ask
Low
2.9
3
High
2.9
3
양
17
마켓
주식
헬스케어
ACIU
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
71.94 M
83.48 M
83.62 M
99.2 M
100.41 M
366.71 M
Valuation ratios
Enterprise value
371.91 M
413.22 M
184.8 M
465.24 M
271.11 M
1.33 B
Price to earnings ratio
—
—
—
—
—
—
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
—
—
—
—
—
—
Price to book ratio
—
—
—
—
—
—
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
—
—
—
—
—
—
Return on equity %
—
—
—
—
—
—
Return on invested capital %
—
—
—
—
—
—
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
—
—
—
—
—
—
Inventory turnover
—
—
—
—
—
—
Asset turnover
—
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
—
—
—
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
—
—
—
—
Net current asset value per share
—
—
—
—
—
—
Tangible book value per share
—
—
—
—
—
—
Working capital per share
—
—
—
—
—
—
Book value per share
—
—
—
—
—
—
뉴스
AC Immune, 뇌 침투 NLRP3 억제제 1상 시험 개시
AC Immune begins phase 1 trial of brain-penetrant NLRP3 inhibitor
2026 Market Outlook: Focus On Pharma For Consistent Returns, Potential Skyrocketing Shares
AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD
Tesla and Rivian among market cap stock movers on Friday
AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's - AC Immune (NASDAQ:ACIU)
AC Immune, 파킨슨병 치료제 임상 2상서 긍정적 결과 발표 후 주가 급등
AC Immune stock rises after positive Parkinson’s disease trial data
AC Immune’s Parkinson’s treatment shows promise in slowing disease
AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates
Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline